Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Combined PKC and MEK inhibition for treating metastatic uveal melanoma
M. S. Sagoo
, J. W. Harbour
, J. Stebbing
,
A. M. Bowcock
Research output
:
Contribution to journal
›
Review article
›
peer-review
28
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Combined PKC and MEK inhibition for treating metastatic uveal melanoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
MEK Inhibitor (MEKi)
100%
Uveal Melanoma
100%
Metastatic Uveal Melanoma
100%
GNA11
75%
Mitogen-activated Protein Kinase
50%
Melanoma
25%
Melanocytic Tumor
25%
Tumor Regression
25%
Signaling Pathway
25%
Metastatic Disease
25%
Most Common Form
25%
Effective Treatment
25%
Activating mutation
25%
Therapeutic Approaches
25%
Pathway Inhibitors
25%
Melanoma Cells
25%
Downstream Effectors
25%
Melanocytes
25%
In Vivo Growth
25%
PKC Activation
25%
MAPK Activation
25%
Uveal Melanoma Cells
25%
MAPK Signaling
25%
Rational Therapeutics
25%
PKC Inhibitor
25%
Oncogenic mutations
25%
Ocular Malignancy
25%
PKC Pathway
25%
Medicine and Dentistry
Metastatic Uvea Melanoma
100%
Uvea Melanoma
100%
Mitogen-Activated Protein Kinase
75%
Cancer
25%
Carcinogenesis
25%
Metastatic Carcinoma
25%
Tumor Regression
25%
Melanocyte
25%
Cell Signaling Pathway
25%
MAPK Signaling
25%
Melanoma
25%
Uveal Melanoma Cell Line
25%
Tumor
25%
Effective Treatment
25%
Pharmacology, Toxicology and Pharmaceutical Science
Uvea Melanoma
100%
Metastatic Uvea Melanoma
100%
Carcinogenesis
20%
Tumor Regression
20%
Melanoma
20%